---
schema_version: "secwatch.filing_event.v1"
accession: "0001517022-25-000004"
form_type: "8-K"
ticker: "AKBA"
cik: "0001517022"
company_name: "Akebia Therapeutics, Inc."
filed_at: "2025-01-13T23:59:59+00:00"
generated_at: "2026-05-28T03:10:09.761917+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Akebia guides cash runway of at least two years, funding Vafseo launch and pipeline

## Summary
- Expects existing cash and cash from ops to fund current plan for at least two years.
- Funding supports U.S. Vafseo launch and planned pipeline advancement.
- CEO John Butler presenting at 43rd Annual J.P. Morgan Healthcare Conference on Jan 16, 2025.
- Cautionary language regarding potential need for additional funding if plan changes.

## SEC filing metadata
- accession: 0001517022-25-000004
- form_type: 8-K
- ticker: AKBA
- cik: 0001517022
- company_name: Akebia Therapeutics, Inc.
- filed_at: 2025-01-13T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1517022/000151702225000004/0001517022-25-000004-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1517022/000151702225000004/akba-20250113.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001517022-25-000004
- JSON: https://secwatch.observer/filing/0001517022-25-000004.json
- Plain text: https://secwatch.observer/filing/0001517022-25-000004.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.